Asterias Biotherapeutics (NYSE: AST) is a clinical-stage biotechnology company focusing on developing and commercializing novel therapies in the fields of cell therapy and regenerative medicine specifically for the areas of neurology and oncology. Asterias is developing AST-VAC1, an autologous product candidate that completed phase II clinical trials for the treatment of acute myelogenous leukemia; and AST-VAC2, an allogeneic, or non-patient specific, cancer vaccine candidate designed to stimulate patient immune responses to telomerase that is in pre-clinical stage. For more information, visit the company’s website at www.asteriasbiotherapeutics.com.
About NetworkNewsWire
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.networknewswire.com
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.net
